Last updated: March 13, 2026
What is NDC 24208-0735?
NDC 24208-0735 refers to a specific formulation of a drug registered in the National Drug Code catalog. Based on publicly available data, this NDC corresponds to Sovaldi (sofosbuvir) 400 mg tablets, used for treating hepatitis C virus (HCV) infections.
Market Landscape
Current Market Size
The hepatitis C drug market has undergone significant changes over the past decade, driven by the introduction of direct-acting antivirals (DAAs) like sofosbuvir. Key figures:
-
Global HCV drug market was valued at approximately $7.6 billion in 2021, with projections to reach $15.2 billion by 2027, growing at a CAGR of 12% from 2022 to 2027 [1].
-
United States: In 2022, the market for hepatitis C treatments was estimated at $4.3 billion, representing a high proportion of global sales.
Key Market Players
- Gilead Sciences: Distributor and manufacturer of Sovaldi.
- Merck & Co.: Offers alternative HCV therapies.
- AbbVie: Provides competing regimens, including Mavyret.
Market Penetration
Gilead’s Sovaldi maintains a sizable share due to its efficacy and early positioning in the market, but competition lowers price points and expands treatment options.
Regulatory Environment
- Sovaldi received FDA approval in 2013.
- Pricing and reimbursement policies vary by country and insurer.
Current Pricing Data
Wholesale Acquisition Cost (WAC)
- The list price for a 28-tablet supply of Sovaldi (400 mg) is approximately $28,000.
- Cost per tablet: $1,000.
Actual Transaction Prices
- In practice, negotiated prices are often lower.
- Insurance reimbursements tend to be around $10,000 to $20,000 per treatment course, depending on discounts and patient assistance programs.
Treatment Course Cost
- Standard treatment duration: 12 weeks.
- Total estimated actual cost: approximately $84,000 to $120,000 per patient.
Price Trends and Projections
Historical Trends
- Initial launch: prices hovered around $84,000 per treatment course.
- As competition increased, prices decreased by approximately 24% between 2015 and 2020.
Projected Price Developments (2023-2028)
| Year |
Estimated Treatment Course Price |
Notes |
| 2023 |
$70,000 – $85,000 |
Stabilization influenced by patent status and generic entry. |
| 2024 |
$65,000 – $80,000 |
Potential for further discounts with biosimilar options. |
| 2025 |
$60,000 – $75,000 |
Risk of price stabilization or slight decline. |
| 2026 |
$55,000 – $70,000 |
Entry of biosimilars and price negotiations. |
| 2027 |
$50,000 – $65,000 |
Potential further declines in negotiated prices. |
| 2028 |
$45,000 – $60,000 |
As biosimilar market stabilizes. |
Factors Influencing Price Trends
- Patent expiration: Expected around 2028 in the United States.
- Biosimilar and generic entry: Could reduce prices by up to 50%.
- Insurance negotiations: Cap prices through formulary management.
- Manufacturing costs: Relatively stable, but could decline with increased volume.
Competitive Dynamics
| Competitor |
Drugs |
Features |
Market Share (est.) |
| Gilead |
Sofosbuvir-based regimens |
Market leader, high efficacy, established supply |
60% |
| Merck |
Erascope (grazoprevir/elbasvir) |
Alternative DAA, similar efficacy |
15% |
| AbbVie |
Mavyret (glecaprevir/pibrentasvir) |
Shorter course, broader genotype coverage |
20% |
| Other |
Generic DAAs |
Entry since patent expiry, price-sensitive |
5% |
Prices for generic versions are expected to be 50-70% lower than branded therapies.
Regulatory and Policy Impact
- Affordable Access Programs: Governments and insurers may negotiate deeper discounts.
- Patent litigation: Delays biosimilar impact, potentially maintaining high prices until 2028.
Risks and Opportunities
Risks
- Patent challenges reducing exclusivity.
- Regulatory delays or bans affecting sales.
- Entry of cheaper generics and biosimilars.
Opportunities
- Expansion into latent markets with previously unapproved indications.
- Development of fixed-dose combinations reducing treatment costs.
- Increasing prevalence of HCV in underserved populations.
Key Takeaways
- The current list price for NDC 24208-0735 is approximately $28,000 per 28 tablets.
- Actual treatment course costs usually range from $84,000 to $120,000.
- Future prices are projected to decline gradually, reaching between $45,000 and $60,000 by 2028.
- Patent expiration and biosimilar entry are primary drivers of downward pricing pressure.
- The market remains competitive among branded regimens and generics, with significant implications for pricing strategies.
FAQs
Q1: When will biosimilars for sofosbuvir be available?
A1: Biosimilar versions are expected to enter the market after patent expiration, projected around 2028.
Q2: How much can prices realistically drop due to biosimilar competition?
A2: Prices might decrease by up to 50-70% compared to current branded therapy prices.
Q3: What factors influence negotiations between manufacturers and payers?
A3: Efficacy, treatment duration, market competition, and volume commitments.
Q4: Are there regional differences in pricing?
A4: Yes, countries with centralized procurement and heavier regulation tend to have lower prices.
Q5: What strategies can manufacturers use to sustain pricing?
A5: Developing fixed-dose combinations, expanding indications, and securing patents for new formulations.
References
[1] Market Research Future. (2022). Hepatitis C Virus Market Insights.
